The Myeloid Genomics Take a look at covers 79 genes, together with these linked to inherited dangers, to detect key genetic adjustments and gives complete genomic profiling for cancers reminiscent of lung, colon, breast, and melanoma.
Learn by:
100 Business Professionals
Learn by
100 Business Professionals
New Delhi: Fortis Hospital’s diagnostics arm, <a id=” captionrendered=”1″ data-src=”https://etimg.etb2bimg.com/photograph/117458538.cms” peak=”442″ href=”/tag/agilus+diagnostics” keywordseo=”Agilus-Diagnostics” loading=”keen” meta.entityid=”Agilus Diagnostics” meta.entityname=”Agilus Diagnostics” meta.hostid=”266″ meta.keywordsubtype=”org” supply=”key phrases” src=”https://img.etb2bimg.com/information/cp/upload-1716881542-ethealthworld.webp” kind=”Normal” weightage=”20″ width=”590″>Agilus Diagnostics, has launched a genome test designed to detect most cancers with a three-day turnaround time (TAT) for check ends in myeloid malignancies. The check additionally gives complete genomic profiling for cancers reminiscent of lung, colon, breast, and melanoma.
The Myeloid genomics check analyzes 79 genes, together with these related to inherited dangers, to establish key genetic adjustments reminiscent of mutations and fusions. This permits personalized treatment suggestions for situations like Acute Myeloid Leukemia (AML) and Myeloproliferative Neoplasms (MPN), the corporate said.
The check identifies mutations, amplifications, and fusion genes, providing actionable insights for focused therapies. With optimized panels for tissue and blood samples, it ensures correct outcomes for each liquid biopsy samples and tissue block samples, the corporate added.
“With our superior genomic testing capabilities, we goal to offer clinicians with the instruments they should make well timed, knowledgeable selections. This not solely improves outcomes but in addition units a brand new benchmark for the healthcare business in India,” stated Dr Anand Ok, Managing Director & CEO of Agilus Diagnostics.
The Indian genome testing market is at present valued at roughly $150 million and is projected to develop at a CAGR of over 15 per cent within the subsequent 5 years. Genomic testing is remodeling most cancers diagnostics by providing actionable insights into a person’s distinctive genetic profile. It permits clinicians to establish particular mutations, tailor therapy plans, and choose therapies with the best efficacy.
Be a part of the group of 2M+ business professionals
Subscribe to our publication to get newest insights & evaluation.
Obtain ETHealthworld App
- Get Realtime updates
- Save your favorite articles
Scan to obtain App
